ARGX ARGENX SE

Nasdaq argenx.com


$ 826.46 $ 7.78 (0.95 %)    

Monday, 03-Nov-2025 15:59:58 EST
QQQ $ 630.50 $ -3.11 (-0.49 %)
DIA $ 472.86 $ -2.20 (-0.46 %)
SPY $ 682.11 $ -2.29 (-0.33 %)
TLT $ 89.66 $ 0.07 (0.08 %)
GLD $ 367.20 $ 0.05 (0.01 %)
$ 826.28
$ 817.67
$ 775.00 x 4
$ 870.00 x 3
$ 809.15 - $ 832.38
$ 510.06 - $ 855.46
335,502
na
50.21B
$ 0.64
$ 60.27
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-argenx-raises-price-target-to-1146

TD Cowen analyst Yaron Werber maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $800 to $1146.

 rbc-capital-maintains-outperform-on-argenx-raises-price-target-to-860

RBC Capital analyst Luca Issi maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $850 to $860.

 evercore-isi-group-maintains-outperform-on-argenx-raises-price-target-to-910

Evercore ISI Group analyst Gavin Clark-Gartner maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target ...

 hc-wainwright--co-maintains-buy-on-argenx-raises-price-target-to-915

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $774...

 argenx-q3-eps-518-beats-430-estimate-sales-1151b-beat-1056b-estimate

argenx (NASDAQ:ARGX) reported quarterly earnings of $5.18 per share which beat the analyst consensus estimate of $4.30 by 20.44...

 argenx-to-present-new-data-highlighting-efficacy-and-safety-of-vyvgart-across-gmg-patient-populations-at-2025-aanem-and-mgfa-scientific-session

argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from...

 argenx-to-present-vyvgart-and-empasiprubart-data-at-aanem-annual-meeting-and-mgfa-scientific-session-in-san-francisco

Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis ...

 wedbush-maintains-outperform-on-argenx-raises-price-target-to-880

Wedbush analyst David Nierengarten maintains argenx (NASDAQ:ARGX) with a Outperform and raises the price target from $800 to...

 morgan-stanley-maintains-overweight-on-argenx-raises-price-target-to-1040

Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $7...

 heres-how-much-100-invested-in-argenx-5-years-ago-would-be-worth-today

argenx (NASDAQ: ARGX) has outperformed the market over the past 5 years by 7.61% on an annualized basis producing an average an...

 price-over-earnings-overview-argenx

In the current market session, argenx Inc. (NASDAQ: ARGX) share price is at $711.62, after a 0.07% increase. Moreover, over the...

 guggenheim-reiterates-buy-on-argenx-maintains-1070-price-target

Guggenheim analyst Yatin Suneja reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $1070 price target.

 fujifilm-biotechnologies-expands-strategic-partnership-with-argenx-to-include-us-manufacturing-operations

Expansion of partnership broadens argenx' manufacturing capabilities in the U.S., supporting its strategy of local-for-loca...

 truist-securities-maintains-buy-on-argenx-raises-price-target-to-918

Truist Securities analyst Joon Lee maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $700 to $918.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION